Labcorp to acquire BioReference Health assets from OPKO for $722 million
Oct 15, 2026, 7:42 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Strategic expansion into more testing domains and the 4Kscore asset could elevate near-term prospects and long-term growth; however, material benefits hinge on regulatory close and integration success.
AI summary
What happened, with direct paths to the underlying reporting
Labcorp will acquire BioReference Health's clinical and specialty testing assets, including the 4Kscore Test, for $722 million cash with a potential $150 million earnout. The deal adds 80+ service centers and broadens Labcorp's portfolio in women's health, urology, and diagnostic analytics, with management projecting about $250 million in first-year revenue after closing, subject to regulatory approvals.
Labcorp to acquire BioReference Health assets from OPKO for $722 million.
Earnout up to $150 million tied to 4Kscore Test revenue.
Adds 80+ patient service centers; expands women's health, urology, and corrections testing.
4Kscore Test, FDA-approved, expands access to prostate cancer risk testing nationwide.
First-year revenue expected around $250 million post-close; regulatory approvals required.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Labcorp reaffirmed its 2026 targets and outlined a constructive, multi-year growth trajectory, including 5-8% revenue CAGR and 8.5-11.5% EPS CAGR through 2029. The plan emphasizes…
Labcorp reported stronger-than-expected Q2 results and raised its full-year profit forecast, driven by steady diagnostic-testing demand and growth in its drug-development services…
Labcorp Holdings reported a solid Q1 with earnings of $4.25, exceeding analysts' forecasts. The company also raised its full-year EPS guidance, reflecting confidence driven by tec…
Labcorp announced an increase in its full-year profit and revenue forecasts after exceeding quarterly expectations, driven by steady demand for diagnostic testing. This developmen…